[Research Progress of Cytokines in the Prognosis of Acute Myeloid Leukemia --Review].

At present, acute myeloid leukemia (AML) is mainly treated with combination medication, high-dose, and early intensification. The treatment has achieved good results, but the long-term treatment effect is still not satisfactory. Studies have shown that the different levels of cytokine expression in AML patients can help AML risk stratification, search for treatment directions and predict the prognosis. It has been confirmed that the expression of IL-1β, IL-6, TNF-α, and TGF-β1 are increased in AML patients, and they all indicate a poor prognosis. However, IL-8, IFN-γ, and CCL5 have great research value in chemotherapy resistance and improvement of treatment effect. This article reviews the research progress of cytokine biomarkers in the prognosis of AML patients.细胞因子在急性髓系白血病预后中的研究进展.目前急性髓系白血病（AML）的治疗以联合用药、大剂量、早期强化为主，且取得了较好的治疗效果，但是远期治疗效果仍令人不满意。研究表明，AML患者细胞因子的不同程度表达有助于AML危险分层、寻找治疗方向以及预测AML患者预后。目前已证实IL-1β、IL-6、TNF-α、TGF-β1在AML患者中高表达，且均提示不良预后，而IL-8、IFN-γ、CCL5在化疗耐药性及改善治疗效果方面具有较大的研究价值。本文就细胞因子类生物标志在AML患者预后中的研究进展作一综述.